SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

UPLOAD Filing

BICYCLE THERAPEUTICS PLC
Date: Aug. 12, 2025 · CIK: 0001761612 · Accession: 0000000000-25-008436

Offering / Registration Process

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 333-289423

Date
August 12, 2025
Author
Division of
Form
UPLOAD
Company
BICYCLE THERAPEUTICS PLC

Letter

Re: Bicycle Therapeutics plc Registration Statement on Form S-3 Filed August 8, 2025 File No. 333-289423 Dear Alethia Young:

August 12, 2025

Alethia Young Chief Financial Officer Bicycle Therapeutics plc Blocks A & B, Portway Building Granta Park Great Abington, Cambridge CB21 6GS United Kingdom

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Jessica Dickerson at 202-551-8013 with any questions.

Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Jaime L. Chase, Esq.

Show Raw Text
<DOCUMENT>
<TYPE>TEXT-EXTRACT
<SEQUENCE>2
<FILENAME>filename2.txt
<TEXT>
 August 12, 2025

Alethia Young
Chief Financial Officer
Bicycle Therapeutics plc
Blocks A & B, Portway Building
Granta Park Great Abington, Cambridge CB21 6GS
United Kingdom

 Re: Bicycle Therapeutics plc
 Registration Statement on Form S-3
 Filed August 8, 2025
 File No. 333-289423
Dear Alethia Young:

 This is to advise you that we have not reviewed and will not review your
registration
statement.

 Please refer to Rules 460 and 461 regarding requests for acceleration.
We remind you
that the company and its management are responsible for the accuracy and
adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action
by the staff.

 Please contact Jessica Dickerson at 202-551-8013 with any questions.

 Sincerely,

 Division of
Corporation Finance
 Office of Life
Sciences
cc: Jaime L. Chase, Esq.
</TEXT>
</DOCUMENT>